Previous Page | Right click this page to print.

Unit 4

Health Consumerism

Who is Vulnerable?

  • Quick fixes
    • Weight loss
    • Muscle gain
    • Sexual dysfunction
  • Serious Illness
    • Cancer
    • AIDS
    • MS
    • Alzheimer’s

FDA Regulations

Strong links, based on scientific evidence, between a food substance and a disease or health condition

  • Examples:
    • Calcium may reduce the risk of the bone disease osteoporosis
    • Folic acid may reduce the risk of neural tube defect-affected pregnancies

Dietary supplements may carry claims that describe the effect of a substance in maintaining the body’s normal structure or function, i.e., “Product B promotes healthy joints and bones”

Dietary Supplements

  • Dietary supplements are not required to undergo government testing or review before they are marketed
  • Supplements can have a drug-like effect that could present risks for people on certain medicines or with certain medical conditions
  • Check with your healthcare professional

Spotting Fraud

  • This treatment is a “cure-all”
  • Statements that claim treatment or cure
  • Promotional claims: “scientific breakthrough” or “secret ingredient”
  • Undocumented case histories
  • Limited availability and pressure to “buy now”
  • Celebrity spokespersons

Sources of Information

Case Study

  • Celebrex and Vioxx released in 1999
  • Claims of relieving arthritis pain safely and more effective than other OTC meds
  • Much more expensive
    • Compare $100 -$140 to $10 per month for aspirin, ibuprofen, and naproxen sodium

Conflict of Interest

  • Study published in JAMA (2000) found Celebrex did reduce risk of ulcers…at the first 6 months of the study
  • At one year out, these results did not hold true
  • Interestingly…the study was funded by Pharmacia, the manufacturer of Celebrex
  • More and more research is being conducted by the drug industry rather than the government
  • Increases the risk of conflict of interest
  • Three-year rule: avoid drugs that have been marketed for less than 3 years, unless no other options. Allows for proper evaluation of medicines.

Previous Page | Right click this page to print.